• Mashup Score: 19

    See the impressive lineup of Late-Breaking Science on tap for presentation in Philadelphia.

    Tweet Tweets with this article
    • Trials of this year's #AHA that intrigue me the most: 1) SELECT on semaglutide 2) ORBITA-2 on PCI 3) DAPA-MI on dapagliflozin 4) AZALEA on abelacimab 5) ARTESIA on apixaban 6) REMAIN-2 on recaticimab 7) A trial of lepodisiran 8) VERVE-101 on gene editing https://t.co/cP74P3GsyW